The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

作者
Xiuli Tao,Ning Li,Ning Wu,Jie He,Jianming Ying,Shugeng Gao,Shuhang Wang,Jie Wang,Zhijie Wang,Yun Ling,Wei Tang,Zewei Zhang
出处
期刊:European Journal of Nuclear Medicine and Molecular Imaging [Springer Science+Business Media]
卷期号:47 (5): 1209-1219 被引量:88
标识
DOI:10.1007/s00259-020-04711-3
摘要

Abstract Purpose Investigate whether 18 F-FDG PET-CT has the potential to predict the major pathologic response (MPR) to neoadjuvant sintilimab in resectable NSCLC patients, and the potential of sifting patients who probably benefit from immunotherapy. Methods Treatment-naive patients with resectable NSCLC (stage IA–IIIB) received two cycles of sintilimab (200 mg, intravenously, day 1 and 22). Surgery was performed between day 29 and 43. PET-CT was obtained at baseline and prior to surgery. The following lean body mass–corrected metabolic parameters were calculated by PET VCAR: SUL max , SUL peak , MTV, TLG, ΔSUL max %, ΔSUL peak %, ΔMTV%, ΔTLG%. PET responses were classified using PERCIST. The above metabolic information on FDG-PET was correlated with the surgical pathology. (Registration Number: ChiCTR-OIC-17013726). Results Thirty-six patients received 2 doses of sintilimab, all of whom underwent PET-CT twice and had radical resection (35) or biopsy (1). MPR occurred in 13 of 36 resected tumors (36.1%, 13/36). The degree of pathological regression was positively correlated with SUL max ( p = 0.036) of scan-1, and was negatively correlated with all metabolic parameters of scan-2, and the percentage changes of the metabolic parameters after neoadjuvant therapy ( p < 0.05). According to PERCIST, 13 patients (36.1%, 13/36) showed partial metabolic response (PMR), 21 (58.3%, 21/36) had stable metabolic disease, and 2 (5.6%, 2/36) had progressive metabolic disease (PMD). There was a significant correlation between the pathological response and the PET responses which were classified using PERCIST. All (100.0%) the PMR (ΔSUL peak % < − 30.0%) tumors showed MPR. Conclusions 18 F-FDG PET-CT can predict MPR to neoadjuvant sintilimab in resectable non-small cell lung cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lili完成签到 ,获得积分10
刚刚
1秒前
酒辞发布了新的文献求助10
1秒前
邓不利多i完成签到,获得积分10
2秒前
zzz发布了新的文献求助10
2秒前
陈y完成签到,获得积分10
2秒前
ny66完成签到,获得积分10
3秒前
3秒前
ish168178发布了新的文献求助10
3秒前
寻123完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
4秒前
珍珠发布了新的文献求助30
4秒前
柒九发布了新的文献求助10
4秒前
4秒前
领导范儿的应助被绯红逍遥采纳,获得10
5秒前
5秒前
kris发布了新的文献求助10
5秒前
QDU的应助被嘟嘟嘟采纳,获得20
5秒前
支摇伽发布了新的文献求助10
5秒前
复嘟嘟完成签到,获得积分10
6秒前
Nole的应助被观的采纳,获得30
6秒前
DW的应助被瑞达采纳,获得10
6秒前
搜集达人的应助被张顺采纳,获得10
6秒前
义气的哈密瓜完成签到,获得积分10
7秒前
搜集达人的应助被Hello_Alina采纳,获得10
7秒前
小黄发布了新的文献求助10
7秒前
Celeste完成签到 ,获得积分10
7秒前
kipo完成签到 ,获得积分10
7秒前
王十七发布了新的文献求助10
7秒前
8秒前
wanci的应助被爽朗的小王同学采纳,获得10
8秒前
瓶子完成签到 ,获得积分10
8秒前
甜美无剑发布了新的文献求助10
8秒前
李健的小迷弟的应助被youyyuy采纳,获得10
9秒前
10秒前
彳亍完成签到,获得积分10
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287